<DOC>
	<DOCNO>NCT00678626</DOCNO>
	<brief_summary>This study assess effectiveness CP- 751,871 give combination docetaxel woman first occurrence advance breast cancer disease . The effectiveness measure progression-free survival duration . Patients follow 2 year date randomization .</brief_summary>
	<brief_title>Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>histologically cytologically confirm diagnosis evidence either metastatic disease ( Stage IV ) locally recurrent disease amenable curative resection radiation therapy ( Stage IIIB ) . Her2negative breast cancer unknown Her2 status . least 1 measurable lesion define RECIST . ECOG status 01 adequate bone marrow , hepatic renal function . leave ventricular ejection fraction great equal 50 % . willingness discontinue hormonal therapy . previous chemotherapy advance disease . prior exposure taxanes ( neo ) adjuvant treatment le 12 month prior randomization . symptomatic brain metastasis . prior antiIGF1R base investigational therapy . peripheral neuropathy great grade 2 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Key word : Docetaxel ; breast cancer ; breast disease ; breast neoplasm ; antineoplastic agent ; neoplasm ; HER-2 negative ; Stage IIIB IV breast cancer .</keyword>
</DOC>